BLRX Bioline Rx Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: BLRX

Price (delayed)

$0.68

Market cap

$49.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.06

Enterprise value

$18.1M

biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'​in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain ...

Highlights
The debt has declined by 13% since the previous quarter and by 6% year-on-year
BLRX's net income has shrunk by 143% YoY and by 16% QoQ
BLRX's EPS has dropped by 100% year-on-year and by 20% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biolinerx.com/
Peers: OMER OMGA

Key stats

What are the main financial stats of BLRX
Market
Shares outstanding
72.8M
Market cap
$49.51M
Enterprise value
$18.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.2
Price to sales (P/S)
9.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.77
Earnings
Revenue
$4.8M
EBIT
-$58.45M
EBITDA
-$57.06M
Free cash flow
-$22.72M
Per share
EPS
-$0.06
Free cash flow per share
-$0.35
Book value per share
$0.21
Revenue per share
$0.07
TBVPS
$0.76
Balance sheet
Total assets
$63.93M
Total liabilities
$50.7M
Debt
$11.59M
Equity
$13.22M
Working capital
$16.33M
Liquidity
Debt to equity
0.88
Current ratio
1.53
Quick ratio
1.43
Net debt/EBITDA
0.55
Margins
EBITDA margin
-1,188.8%
Gross margin
23.1%
Net margin
-1,262.8%
Operating margin
-1,035.3%
Efficiency
Return on assets
-99.2%
Return on equity
-280.2%
Return on invested capital
N/A
Return on capital employed
-176.7%
Return on sales
-1,217.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLRX stock price

How has the Bioline Rx stock price performed over time
Intraday
3.03%
1 week
11.48%
1 month
-17.87%
1 year
-41.88%
YTD
-56.69%
QTD
-39.29%

Financial performance

How have Bioline Rx's revenue and profit performed over time
Revenue
$4.8M
Gross profit
$1.11M
Operating income
-$49.69M
Net income
-$60.61M
Gross margin
23.1%
Net margin
-1,262.8%
BLRX's net income has shrunk by 143% YoY and by 16% QoQ
Bioline Rx's operating income has plunged by 70% YoY and by 26% from the previous quarter

Growth

What is Bioline Rx's growth rate over time

Valuation

What is Bioline Rx stock price valuation
P/E
N/A
P/B
3.2
P/S
9.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.77
BLRX's EPS has dropped by 100% year-on-year and by 20% since the previous quarter
The equity has plunged by 74% YoY
The stock's price to book (P/B) is 60% more than its 5-year quarterly average of 2.0 but 42% less than its last 4 quarters average of 5.5

Efficiency

How efficient is Bioline Rx business performance
BLRX's return on assets has dropped by 199% year-on-year and by 21% since the previous quarter
Bioline Rx's return on equity has shrunk by 66% QoQ

Dividends

What is BLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLRX.

Financial health

How did Bioline Rx financials performed over time
The company's total assets is 26% higher than its total liabilities
BLRX's total liabilities has surged by 98% year-on-year and by 28% since the previous quarter
Bioline Rx's quick ratio has shrunk by 71% YoY and by 20% QoQ
The debt is 12% smaller than the equity
The equity has plunged by 74% YoY
The debt to equity has contracted by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.